Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
详细信息 查看全文
- 作者：Ming-Tsung Lin (1)
Yeh-Pin Chou (1)
Tsung-Hui Hu (1)
Hsien-Chung Yu (2)
Yu-Chun Hsu (3)
Ming-Chao Tsai (1)
Po-Lin Tseng (1)
Kuo-Chin Chang (1)
Yi-Hao Yen (1)
King-Wah Chiu (1) - 刊名：Archives of Virology
- 出版年：2014
- 出版时间：January 2014
- 年：2014
- 卷：159
- 期：1
- 页码：29-37
- 全文大小：256 KB
- 作者单位：Ming-Tsung Lin (1)
Yeh-Pin Chou (1)
Tsung-Hui Hu (1)
Hsien-Chung Yu (2)
Yu-Chun Hsu (3)
Ming-Chao Tsai (1)
Po-Lin Tseng (1)
Kuo-Chin Chang (1)
Yi-Hao Yen (1)
King-Wah Chiu (1)
1. Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Sung Dist., Kaohsiung, 833, Taiwan
2. Division of Gastroenterology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
3. Department of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan - ISSN：1432-8798
文摘
We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log10 IU/mL]: group 1, ?.149; group 2, -0.081; group 3, ?.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log10 IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (?.060 Log10 IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (?.050 Log10 IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.